AAMP is a binding partner of costimulatory human B7-H3

Abstract Background Targeted immunotherapies are of growing interest in the treatment of various cancers. B7 homolog 3 protein (B7-H3), a member of the co-stimulatory/-inhibitory B7-family, exerts immunosuppressive and pro-tumorigenic functions in various cancer types and is under evaluation in ongoing clinical trials. Unfortunately, interaction partner(s) remain unknown which restricts the druggability. Methods Aiming to identify potential binding partner(s) of B7-H3, a yeast two-hybrid and a mass spectrometry screen were performed. Potential candidates were evaluated by bimolecular fluorescence complementation (BiFC) assay, co-immunoprecipitation (co-IP), and functionally in a 3H-thymidine proliferation assay of Jurkat cells, a T-cell lineage cell line. Prognostic value of angio-associated migratory cell protein (AAMP) and B7-H3 expression was evaluated in isocitrate dehydrogenase 1 wildtype (IDH1wt) glioblastoma (GBM) patients from The Cancer Genome Atlas (TCGA)-GBM cohort. Results Of the screening candidates, CD164, AAMP, PTPRA, and SLAMF7 could be substantiated via BiFC. AAMP binding could be further confirmed via co-IP and on a functional level. AAMP was ubiquitously expressed in glioma cells, immune cells, and glioma tissue, but did not correlate with glioma grade. Finally, an interaction between AAMP and B7-H3 could be observed on expression level, hinting toward a combined synergistic effect. Conclusions AAMP was identified as a novel interaction partner of B7-H3, opening new possibilities to create a targeted therapy against the pro-tumorigenic costimulatory protein B7-H3.

[1]  Y. Saeys,et al.  Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization , 2021, Nature Neuroscience.

[2]  H. Shimada,et al.  Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma , 2021, Nature communications.

[3]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[4]  Yuelong Wang,et al.  Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy , 2020, Theranostics.

[5]  M. Knoll,et al.  LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance , 2020, Frontiers in Oncology.

[6]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[7]  Ligang Chen,et al.  B7-H3 Regulates Glioma Growth and Cell Invasion Through a JAK2/STAT3/Slug-Dependent Signaling Pathway , 2020, OncoTargets and therapy.

[8]  Che A. Stafford,et al.  NOD Signaling and Cell Death , 2019, Front. Cell Dev. Biol..

[9]  Mariella G. Filbin,et al.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.

[10]  Meijia Yang,et al.  B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma , 2019, Molecular therapy oncolytics.

[11]  Athena W Wong,et al.  A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155 , 2019, Molecular & Cellular Proteomics.

[12]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[13]  P. Dong,et al.  B7H3 As a Promoter of Metastasis and Promising Therapeutic Target , 2018, Front. Oncol..

[14]  M. Weller,et al.  Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate , 2018, Nature Medicine.

[15]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[16]  Steven D Chang,et al.  Single-Cell RNAseq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma , 2017, bioRxiv.

[17]  T. Mak,et al.  Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function , 2017, Cell Research.

[18]  Maheedhara R. Guda,et al.  B7-H3 role in the immune landscape of cancer. , 2017, American journal of clinical and experimental immunology.

[19]  M. Schoenberg,et al.  The third group of the B7‐CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7‐H3 , 2017, Immunological reviews.

[20]  K. Moraes,et al.  MicroRNA Profiling of the Effect of the Heptapeptide Angiotensin-(1-7) in A549 Lung Tumor Cells Reveals a Role for miRNA149-3p in Cellular Migration Processes , 2016, PloS one.

[21]  W. Wick,et al.  Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy , 2016, Oncotarget.

[22]  X. Zang,et al.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy , 2016, Clinical Cancer Research.

[23]  Chul Kim,et al.  Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers , 2016, Human vaccines & immunotherapeutics.

[24]  H. Carlisle,et al.  Identification of modulators of autophagic flux in an image-based high content siRNA screen , 2016, Autophagy.

[25]  Chi‐Huey Wong,et al.  Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response , 2015, Proceedings of the National Academy of Sciences.

[26]  Guixue Wang,et al.  AAMP Regulates Endothelial Cell Migration and Angiogenesis Through RhoA/Rho Kinase Signaling , 2015, Annals of Biomedical Engineering.

[27]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[28]  M. Weller,et al.  Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity? , 2014, Journal of neurochemistry.

[29]  Y. Mao,et al.  B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients , 2014, Oncology letters.

[30]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[31]  R. Parkhouse,et al.  Insights into the molecular basis of the NOD 2 signalling pathway , 2014 .

[32]  W. Jiang,et al.  The impact of angio-associated migratory cell protein (AAMP) on breast cancer cells in vitro and its clinical significance. , 2013, Anticancer research.

[33]  M. Weller,et al.  Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness , 2011, Clinical Cancer Research.

[34]  Ming Zhou,et al.  B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation , 2011, Molecular Cancer Therapeutics.

[35]  M. Azuma,et al.  Enhancement of effector CD8+ T‐cell function by tumour‐associated B7‐H3 and modulation of its counter‐receptor triggering receptor expressed on myeloid cell‐like transcript 2 at tumour sites , 2010, Immunology.

[36]  David P. Kreil,et al.  B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction , 2009, European journal of immunology.

[37]  M. Azuma,et al.  Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses , 2008, Proceedings of the National Academy of Sciences.

[38]  X. Zang,et al.  The contrasting role of B7-H3 , 2008, Proceedings of the National Academy of Sciences.

[39]  L. Moretta,et al.  Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Tagawa,et al.  Stage-specific expression of Clast6/E3/LAPTM5 during B cell differentiation: elevated expression in human B lymphomas. , 2003, International journal of oncology.

[41]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[42]  D. Moul,et al.  Angio-associated migratory cell protein is expressed as an extracellular protein by blood-vessel-associated mesenchymal cells. , 1999, Microvascular research.

[43]  L. Liotta,et al.  Identification of a new immunoglobulin superfamily protein expressed in blood vessels with a heparin-binding consensus sequence. , 1995, Cancer research.